IQInvest research note
25 AUG 2026 · 14:46 ET
BMY
Bristol-Myers Squibb Company
$67.39
$0.11 (+0.17%)up 0.17%
25 August 2026 · delayed 15+ min
C
Cut-offs are the grader's own: 97+ for an A+, below 60 is an F.
Bristol-Myers Squibb Company earns a C on good profit margins (>10%) and strong ROE (>20%) but high debt-to-equity ratio (>2.0) and low Sharpe ratio (0.21). Good investment opportunity with solid fundamentals.
Adjusted for Moderate investors, Medium-term investors 8.0% suggested allocation Change these
IQ-BMY-20260825engine v1 · 7-category weighted scorecard